Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.

Simple item page
dc.contributor.authorBiswas, Gen_US
dc.contributor.authorParikh, P Men_US
dc.contributor.authorNair, Ren_US
dc.contributor.authorBhagwat, Ren_US
dc.contributor.authorBakshi, Aen_US
dc.contributor.authorPrabhash, Ken_US
dc.contributor.authorVora, Aen_US
dc.contributor.authorGupta, Sen_US
dc.contributor.authorPai, V Ren_US
dc.contributor.authorMenon, Hen_US
dc.contributor.authorSastry, P S R Ken_US
dc.date.accessioned2006-01-03en_US
dc.date.accessioned2009-05-31T02:40:51Z
dc.date.available2006-01-03en_US
dc.date.available2009-05-31T02:40:51Z
dc.date.issued2006-01-03en_US
dc.description.abstractRituximab has been used extensively in lymphoproliferative disorders. We evaluated the results of 64 consecutive patients treated between 2001 and 2004 at our institution. This included 54 males and 10 females. The median age was 54 years (range 17 to 85 years). One-fourth of patients were above 60 years. The histology was aggressive NHL in 35, indolent NHL in 22 and 7 cases were diagnosed as CLL. Among NHL, sixteen were in early stage (I/II) and the remaining forty-one were in advanced stage (III/IV) of disease. B symptoms were present in 47% of cases. A total of 33 were de novo cases and 31 were previously treated. Rituximab monotherapy was used in 17 cases. Rituximab was used in combination with chemotherapy in the other 47 cases. Infusional toxicity included anaphylaxis in one, hypotension in one and minor infusional reactions in four others. The patient who developed anaphylaxis required discontinuation of further Rituximab. Growth factors were used in 25 patients. Febrile neutropenia occurred in 19 patients. The overall RR (CR + PR) was 72%. One patient had stable disease and progressive disease was documented in 17 patients. A total of seven patients died, three due to progressive disease, three due to chemotherapy related toxicity and one due to an unrelated cause. We conclude that Rituximab is a valuable addition to the treatment armamentarium of lymphoproliferative disorders.en_US
dc.description.affiliationDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.en_US
dc.identifier.citationBiswas G, Parikh PM, Nair R, Bhagwat R, Bakshi A, Prabhash K, Vora A, Gupta S, Pai VR, Menon H, Sastry PS. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience. Journal of the Association of Physicians of India. 2006 Jan; 54(): 29-33en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/93250
dc.language.isoengen_US
dc.source.urihttps://www.japi.orgen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAntibodies, Monoclonal --adverse effectsen_US
dc.subject.meshAntigens, CD20 --drug effectsen_US
dc.subject.meshAntineoplastic Agents --adverse effectsen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIndiaen_US
dc.subject.meshLymphoma, Non-Hodgkin --drug therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProto-Oncogene Proteins c-bcl-2 --drug effectsen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Rateen_US
dc.titleRituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Association of Physicians of India